A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT01999335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the Phase 1 part of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of oprozomib in combination with pomalidomide and dexamethasone in adults with primary refractory or relapsed and refractory multiple myeloma. The purpose of the Phase 3 part of the study is to compare the efficacy for adults with primary refractory or relapsed and refractory multiple myeloma who are randomized to either oprozomib or placebo in combination with pomalidomide and dexamethasone.
Study identification
- NCT ID
- NCT01999335
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2014 (Actual)
- Primary completion
- Apr 25, 2019 (Actual)
- Completion
- Apr 25, 2019 (Actual)
- Last update posted
- Apr 27, 2021
2014 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates For Research and Exellence, cCare | Encinitas | California | — | — |
| James R. Berenson, MD, Inc. | West Hollywood | California | — | — |
| Innovative Clinical Research Institute | Whittier | California | — | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | — | — |
| Oncology Hematology West PC, dba Nebraska Cancer Specialists | Omaha | Nebraska | — | — |
| Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York | — | — |
| Levine Cancer Institute | Charlotte | North Carolina | — | — |
| Duke University Medical Center | Durham | North Carolina | — | — |
| Willamette Valley Cancer Institute and Research Center | Springfield | Oregon | — | — |
| Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | — | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Tennessee Oncology, PLLC / Sarah Cannon Research Institute | Nashville | Tennessee | — | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | — | — |
| Cancer Care Centers of South Texas-HOAST | San Antonio | Texas | — | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | — | — |
| Virginia Oncology Associates | Norfolk | Virginia | — | — |
| Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01999335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01999335 live on ClinicalTrials.gov.